Archive for April, 2010

« Previous Entries

Three Drugmakers Post Increases In First-Quarter Sales, Profits.

Friday, April 30th, 2010

The AP (4/30, Johnson) reports, “Three top drugmakers on Thursday posted healthy increases in first-quarter sales and profits, with strong sales of key drugs buoying Bristol-Myers Squibb Co., AstraZeneca LP and Sanofi-Aventis SA.” But, the AP adds, “pharmaceutical reports won’t necessarily be as rosy for the next three quarters, due to the new US health […]

Phosphate consumption may accelerate signs of aging

Friday, April 30th, 2010

Source: Med Wire News High phosphate levels act to accelerate signs of aging such as skin atrophication, show results from a study in mice. The researchers believe this finding could be important as phosphates are routinely added to processed foods and soft drinks. “Soda is the caffeine delivery vehicle of choice for millions of people […]

Inflammation compromises HDL protective ability

Friday, April 30th, 2010

Source: MedWire News High levels of high-density lipoprotein (HDL) cholesterol are unable to protect men with elevated C-reactive protein (CRP) levels against cardiovascular (CV) events, shows research. The study also supports the view, previously reported by MedWire News, that people’s vascular risk rises in line with the size of their HDL particles. James Coretti (University of […]

Seroquel Recommended By European Drug Regulators As Add-On Treatment For Depression.

Tuesday, April 27th, 2010

The AP (4/24) reported, “AstraZeneca PLC says its schizophrenia drug Seroquel XR [quetiapine] has been recommended by” the European Medicines Agency “as an add-on treatment for depression.” The agency’s decision “overturns an earlier rejection for the drug’s new use from the Netherlands, which was acting as a reference state for the EU.” The Wall Street […]

Metformin May Improve Ability Of Bicalutamide To Slow Proliferation In Hormone-Resistant Prostate Cancer Cell Lines.

Tuesday, April 27th, 2010

MedPage Today (4/24, Susman) reported that “the commonly prescribed anti-diabetes drug metformin appears to improve the ability of bicalutamide (Casodex), an androgen ablation drug, to slow proliferation in hormone-resistant prostate cancer cell lines,” according to a study presented at the annual meeting of the American Association for Cancer Research. Researchers said that “combining metformin with […]

Hypertension more prevalent in youth with Type 2 than Type 1 diabetes

Thursday, April 22nd, 2010

Source: MedWire News Children and adolescents with Type 2 diabetes are more likely to have high blood pressure (BP) than those with Type 1 diabetes, report US researchers. “There is limited information about the prevalence of elevated BP in youth with diabetes mellitus,” say Ronny Bell (Wake Forest University School of Medicine, Winston Salem, North […]

Medication nonadherence in schizophrenia linked to suicide risk

Wednesday, April 21st, 2010

Source: MedWire News Poor adherence to antipsychotic drugs in outpatients with schizophrenia can be predicted by current alcohol and substance abuse and a history of previous nonadherence, among other factors, researchers report. Patients who reported poor medication adherence were at increased risk for relapse, hospitalization, and suicide attempts – a largely unexplored consequence of nonadherence. […]

Tamoxifen, Raloxifene May Reduce Breast Cancer Risk.

Wednesday, April 21st, 2010

ABC World News (4/19, story 8, 0:35, Sawyer) reported that two drugs, tamoxifen and raloxifene, may help prevent breast cancer, according to a study funded by the National Cancer Institute. The Los Angeles Times (4/20, Maugh) reports that “the trial enrolled 19,747 post-menopausal women over the age of 35 who had an above-normal risk of […]

Intensive glucose control reduces MI risk in Type 2 diabetics

Wednesday, April 21st, 2010

Source: MedWire News Results from a systematic review and meta-analysis show that intensive glucose control in patients with Type 2 diabetes reduces the risk for non-fatal myocardial infarction (MI) compared with conventional glucose control. However, intensive glucose control did not significantly reduce the rate of mortality or non-fatal stroke versus conventional treatment. “Although intensive glucose […]

Exenatide treatment adds extra benefit to lifestyle modification

Monday, April 19th, 2010

Treatment with exenatide (Byetta) plus lifestyle modification significantly improves glycemic control, reduces weight, and decreases blood pressure in overweight Type 2 diabetics taking metformin or a sulfonylurea compared with lifestyle modification alone, report US researchers. “Lifestyle modification is an effective and important treatment component for hyperglycemia and associated risk factors in patients with, or at […]

« Previous Entries